Revolution Medicines RVMDW
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Revolution Medicines (RVMDW) Business Model and Operations Summary
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Key Insights
Revolution Medicines (RVMDW) Core Market Data and Business Metrics
Latest Closing Price
$0.255Market Cap
$7.44 MillionAverage Trade Volume
20,273.845 SharesTotal Outstanding Shares
186.26 Million SharesCEO
Dr. Mark A. Goldsmith Ph.D.Total Employees
616IPO Date
November 17, 2023SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
700 Saginaw Dr, Redwood City, CA, 94063
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Short Interest
Short Interest
This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.
Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Historical Stock Splits
| Execution Date | Split Amount |
|---|